Gene therapy for dopamine replacement

Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Progress in brain research (Impact Factor: 5.1). 01/2010; 184:221-35. DOI: 10.1016/S0079-6123(10)84012-9
Source: PubMed

ABSTRACT Dopamine replacement for Parkinson's disease (PD) have seen three major iterations of improvements since the introduction of l-3,4-dihydroxyphenylalanine (l-DOPA) pharmacotherapy: dopamine receptor agonists, ex vivo gene transfer for cell transplantation and most recently in vivo gene therapy. In this chapter, we describe the principles behind viral vector-mediated enzyme replacement in PD. We focus on the enzymes involved in the dopamine synthesis and their internal regulation, the early experimental work on gene therapy using different viral vector types and selection of transgenes, and finally discuss the recently completed early phase clinical trials in PD patients.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The demonstration that dopamine loss is the key pathological feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics. This review will discuss the significant progress that has been made in the development of new pharmacological and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s. However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades. The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come. It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 09/2011; 37(1):213-46. DOI:10.1038/npp.2011.212 · 7.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    Edited by Moses P. Adoga, 01/2012; Intech Publishers, Croatia, Europe.., ISBN: 978-953-51-0369-1
  • Source
    Molecular Virology, 03/2012; , ISBN: 978-953-51-0369-1
Show more